BOCA RATON, Fla., Oct. 9, 2017 /PRNewswire/ -- Sensus
Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in the treatment of non-melanoma skin cancers and
keloids with Superficial Radiation Therapy (SRT), announces that at the American Society for Dermatologic Surgery (ASDS) annual
meeting, which took place October 5 th-8th in Chicago, an abstract was presented illustrating the low recurrence rate of keloids post keloidectomy with a
biological effective dose 30 (BED 30) of SRT. Recurrences of keloids at sites of previously excised keloids are notorious in that
approximately 71% of cases recur following a keloid excision alone. In comparison, the abstract reports a significantly lower
keloid recurrence rate, less than 2%, when combining keloidectomy and excision site treatment with SRT (BED 30).
"We are thrilled that an abstract detailing the advantages of SRT for the treatment and prevention of keloids was featured at
the largest organization representing dermatologic surgeons," said Joe Sardano, President and CEO
of Sensus Healthcare. "The abstract highlights SRT as a safe option in treating existing keloid conditions and is most effective
in reducing the recurrence rate of keloids when combined with excision surgery."
Authored by Dr. Brian Berman, M.D., Ph.D. and presented at ASDS by Mark
Nestor, M.D., Ph.D., the abstract, entitled "Low Rate of Keloid Recurrences Following Treatment of Keloidectomy Sites
with a Biological Effective Dose 30 of Superficial Radiation," will also be presented at the upcoming Fall Clinical
Dermatology Conference on October 12-15 th at The Wynn in Las
Vegas, NV.
About American Society for Dermatologic Surgery
American Society for Dermatologic Surgery (ASDS) is the largest specialty organization exclusively representing dermatologic
surgeons who have unique training and experience to treat the health, function and beauty of your skin. ASDS members are pioneers
in the field. Many are involved in the clinical studies that bring popular treatments to revitalize skin and fill and diminish
wrinkles to the forefront. Their work has helped create and enhance many of the devices that remove blemishes, hair and fat, and
tighten skin. Dermatologic surgeons also are experts in skin cancer prevention, detection and treatment. As the incidence of skin
cancer rises, dermatologic surgeons are committed to taking steps to minimize the life-threatening effects of this disease. For
more information, visit asds.net.
About Sensus Healthcare
Sensus Healthcare, Inc. is a medical device company that is committed to providing non-invasive and cost-effective treatment
for non-melanoma skin cancers and keloids. Sensus uses a proprietary low energy X-ray technology known as superficial radiation
therapy (SRT), which is a result of over a decade of dedicated research and development. Sensus has successfully incorporated SRT
therapy into its portfolio of treatment devices, the SRT-100™ and SRT-100 Vision™. To date, SRT technology has been used to
effectively and safely treat oncological and non-oncological skin conditions in thousands of patients. For more information,
visit http://www.sensushealthcare.com.
Contact:
LHA Investor Relations
Kim Sutton Golodetz
(212) 838-3777
kgolodetz@lhai.com
View original content:http://www.prnewswire.com/news-releases/sensus-healthcare-announces-abstract-on-treatment-of-keloids-with-srt-at-the-2017-american-society-for-dermatologic-surgery-annual-meeting-300532827.html
SOURCE Sensus Healthcare